CERRITOS, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology practices in the country, today announced that Dr. Daniel Virnich, TOI’s Chief Executive Officer, will participate at the following investor conferences:
Jefferies Global Healthcare Conference
Date: June 6th, 2024
Fireside Chat: 9:00am Eastern Time
TOI Participant: Daniel Virnich, M.D., MBA, Chief Executive Officer
Location: New York City, NY
Truist Securities Healthcare Disruptors & Digital Health Summit
Date: June 26th, 2024
Panel: 1:00pm Eastern Time
TOI Participant: Daniel Virnich, M.D., MBA, Chief Executive Officer
Location: New York City, NY
Interested investors and other parties may listen to simultaneous webcasts of the presentations by logging onto the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/. The online replay will be available for a limited time shortly following the call.
About The Oncology Institute, Inc.
Founded in 2007, The Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.8 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 110+ employed clinicians and over 70 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Contacts
Investors
Solebury Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.13 |
Daily Change: | -0.05 -26.67 |
Daily Volume: | 14,714,212 |
Market Cap: | US$9.960M |
November 13, 2024 November 11, 2024 September 30, 2024 August 13, 2024 May 14, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB